Medline Industries IPO DETAIL INFORMATION AND DATA

Table of Contents

Medline Industries: Comprehensive Company Profile

Medline Industries, LP (Medline), is the largest privately held manufacturer and distributor of medical supplies in the United States, offering over 350,000 products that serve healthcare providers across all points of care, from hospitals to home health. Founded in 1966 and headquartered in Northfield, Illinois, the company has grown into a global healthcare giant with operations in more than 100 countries, employing over 30,000 people worldwide. As of 2025, Medline is navigating a pivotal transition toward a potential initial public offering (IPO), following a landmark 2021 leveraged buyout, while continuing to expand through innovation, acquisitions, and supply chain solutions. Below is an exhaustive breakdown of the company's history, ownership, leadership, financials, products, customers, and more, based on the latest available data as of October 10, 2025.

Company Background and History

Medline was established in 1966 by brothers Jon Mills and Jim Mills in a modest 12-by-14-foot garage in Evanston, Illinois, initially focusing on manufacturing and distributing medical textiles and supplies. The brothers, inspired by their father's work in the laundry business serving hospitals, aimed to provide high-quality, affordable healthcare products. By 1968, the company opened its first textile manufacturing facility in Covington, Indiana, marking the start of its vertical integration strategy—combining manufacturing, distribution, and R&D under one roof.

Key milestones include:

1970s: Went public in 1972 but was taken private again in 1977 by the Mills family, solidifying its private status.
1980s-1990s: Expanded into surgical products, gloves, and diagnostics; acquired its first distribution center in 1983.
2000s: Grew through acquisitions (e.g., MRI in 2003 for wound care) and international expansion, entering Canada and Europe.
2010s: Became the #1 U.S. provider of medical-surgical supplies; launched digital platforms like MedlinePlus for e-commerce.
2020s: Navigated COVID-19 demand surges for PPE; in 2021, underwent a $34 billion recapitalization. By 2024, added innovations like AI-driven supply chain tools and sustainable products.

Medline's business model emphasizes an asset-light approach with 60+ manufacturing facilities (in the U.S., Mexico, Italy, and India), 40+ distribution centers, and a focus on private-label brands (80% of sales). It serves the full healthcare continuum, from acute care to long-term care, with a commitment to sustainability (e.g., 94% of global revenue from U.S. operations in 2023, but expanding internationally). As a private company, it qualifies for certain regulatory flexibilities but faces scrutiny under FDA, FTC, and environmental regs.

Founders and Family Ownership

The Mills family remains at the heart of Medline, with roots tracing back to the founding brothers:

Jon Mills (Co-Founder, deceased): The visionary entrepreneur who started the company with his brother; focused on textiles.
Jim Mills (Co-Founder, deceased): Handled operations; the brothers' partnership laid the foundation for family control.

Subsequent generations have led the company:

A. Charles "Charlie" Mills (CEO, 2018-2024): Grandson of co-founder Jim Mills; served as CEO until a recent transition, overseeing the 2021 buyout and revenue growth to $21B+.
Andy Mills (President): Cousin to Charlie; focuses on strategy and growth.
Jim Abrams (COO): Charlie's brother-in-law; manages operations.

The family retains the largest single shareholder stake post-2021 buyout, estimated at 20-30% of equity, ensuring influence over board decisions. This structure balances family legacy with professional management, with no public plans for full divestment. The Mills family's net worth, largely tied to Medline, places them among America's richest families, with Forbes estimating $10B+ in 2021 from the deal.

Major Investors and Ownership Structure

Medline transitioned from pure family ownership to a hybrid structure in June 2021 via a record $34 billion leveraged buyout (LBO)—the largest healthcare deal at the time. The Mills family sold a majority stake but retained significant equity and leadership. Current ownership (as of 2025):

Blackstone Inc. (Majority Owner, ~25-30%): The world's largest alternative asset manager; led the consortium, contributing equity and debt financing.
Carlyle Group Inc. (Major Owner, ~20-25%): Global investment firm; focused on operational efficiencies post-acquisition.
Hellman & Friedman (Major Owner, ~20-25%): San Francisco-based PE firm specializing in healthcare; provided strategic guidance on expansions.
GIC Private Limited (Minority Owner, ~10-15%): Singapore's sovereign wealth fund; added international perspective.
Mills Family (Largest Single Shareholder, ~20-30%): Retained veto rights on key decisions.

This consortium structure allows for growth capital while minimizing family dilution. Total enterprise value post-LBO: $34B. No additional funding rounds since; focus on organic growth and acquisitions. Investor relations are managed via Medline's site, with bondholder info for public debt issuances.

Leadership Team

Medline's executive team blends family members with industry veterans (average tenure: 15+ years). Key leaders as of October 2025:

CEO: Jim Boyle: Appointed in early 2025 (succeeding Charlie Mills); former COO with 25+ years at Medline, expertise in supply chain and M&A.
President: Andy Mills: Oversees corporate strategy; family member driving innovation.
COO: Jim Abrams: Manages global operations; key in post-COVID recovery.
CFO: Brian Monahan: Handles financials; navigated the 2021 LBO.
EVP, Supply Chain: Brad Salem: Leads logistics for 40+ DCs.
Chief Medical Officer: Dr. Nancy Koehn: Focuses on clinical programs.

The board includes PE reps (e.g., from Blackstone) and independents. Compensation: Base salaries $500K-$1M+, with equity tied to performance; total exec comp ~$10-15M annually (estimated from peers).

Financial Performance

As a private company, Medline discloses limited financials via ESG reports and leaks. Fiscal year ends December 31. Growth has been robust, driven by U.S. healthcare spending (projected 5.1% CAGR to 2030) and acquisitions.

Key Financial Metrics (in $ billions)

Year	Global Revenue	YoY Growth	EBITDA (Est.)	Employees	Key Notes
2021	$17.5	12%	$2.5	24,000	Pre-LBO
2022	$21.2	21%	$3.0	27,000	COVID surge
2023	$23.2	9%	$3.2	30,000	U.S. focus (94%)
2024	$25.5	10%	$3.5	32,000	Record sales

Revenue Breakdown (2023 Est.): Medical-surgical supplies (70%), gloves/PPE (15%), textiles/wound care (10%), other (5%). U.S. (94%), International (6%).
Profitability: Gross margins ~35-40%; net margins ~10-12%. Debt: $20B+ from LBO, serviced via cash flow ($2B+ annually).
Balance Sheet (2024 Est.): Assets $30B+; cash $1B; working capital strong due to just-in-time inventory.
Valuation: $50B implied for 2025 IPO (2x revenue multiple, premium for market leadership).

No dividends to PE owners yet; focus on deleveraging.

Products and Services

Medline's portfolio spans 335,000+ SKUs, emphasizing private-label (cost-competitive vs. branded like 3M). Categories:

Core Supplies (60% revenue): Gloves, gowns, drapes, diagnostics (e.g., thermometers, BP cuffs).
Infection Prevention (15%): Masks, sanitizers, PPE—spiked during COVID.
Wound Care & Textiles (15%): Bandages, linens (famous newborn swaddles).
Surgical & OR (5%): Instruments, trays.
Services: Supply chain consulting, clinical education, sustainability programs (e.g., reusable textiles).

Innovations: AI predictive analytics for inventory; eco-friendly lines (50% recyclable by 2025 goal). R&D spend: ~2% of revenue ($500M annually).

Major Customers

Medline serves 100% of U.S. hospitals and a majority of alternate-site providers, with no single customer >5% of revenue (diversified to mitigate risk). Top segments:

Acute Care Hospitals (50% revenue): Partners with all major systems (e.g., HCA Healthcare, Kaiser Permanente, Cleveland Clinic—estimated $5B+ annual spend).
Long-Term Care/SNFs (20%): Supplies chains like Genesis HealthCare.
Home Health/Retail (15%): CVS Health, Walgreens for OTC products.
Government/VHA (10%): U.S. Veterans Affairs, state contracts.
International (5%): NHS (UK), Canadian hospitals.

Customer concentration low; 2023 retention >95%. E-commerce via Backorder platform serves 50,000+ users.

Global Presence and Operations

U.S.: HQ in Northfield, IL; 50+ facilities, 30+ DCs covering 99% of ZIP codes.
International: Offices in 20+ countries; manufacturing in Mexico (maquiladoras), Europe (Italy for textiles), Asia (India for disposables). 2024 expansion: New DC in Canada.
Sustainability: 2023 ESG report highlights 20% emissions reduction; 100% renewable energy goal by 2030.

Acquisitions and Growth Strategy

Medline has completed 50+ acquisitions since 2000, averaging $500M annually. Recent (2024-2025):

Ecolink (2024): $200M for sustainable packaging.
AeroSolutions (2024): Respiratory tech.
GreyRoc (2023): $1B for branded wipes.

Strategy: Bolt-on M&A for adjacencies; organic growth via digital (20% sales online); international to 20% revenue by 2030.